WO2000010569A1 - Derives heterocycliques azotes de carboxamide ou certains de leurs sels et antiviraux les contenant les deux - Google Patents
Derives heterocycliques azotes de carboxamide ou certains de leurs sels et antiviraux les contenant les deux Download PDFInfo
- Publication number
- WO2000010569A1 WO2000010569A1 PCT/JP1999/004429 JP9904429W WO0010569A1 WO 2000010569 A1 WO2000010569 A1 WO 2000010569A1 JP 9904429 W JP9904429 W JP 9904429W WO 0010569 A1 WO0010569 A1 WO 0010569A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ring
- virus
- substituted
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
Definitions
- the present invention relates to an antiviral agent containing a nitrogen-containing heterocyclic carboxamide derivative or a salt thereof.
- antiviral agents are classified according to the target virus, for example, acyclovir and vidarabine for herpes virus; ganciclovir and foscarnet for cytomegalovirus; For flame viruses, an interface is used.
- influenza virus is the central virus of the case syndrome, which has periodically hit civilization and caused tens of millions of deaths. In recent years, the number of deaths has been decreasing due to improvements in hygiene and nutrition, but the epidemic has been repeated every year, and there is concern about the outbreak of the new virus.
- Vaccine prevention is widely practiced for influenza virus, and amantadine and ribavirin are used as low molecular weight compounds.
- Amantadine has been used to prevent and treat influenza, but its mechanism of action is said to inhibit the fusion of influenza virus with cell membranes, and is effective against influenza A virus. However, it is pointed out that it is ineffective against influenza B virus, that a resistant virus appears, and that side effects such as neuropathy occur. Limantadine, a derivative of amantadine, has improved antiviral activity but has not overcome its side effects. Also, rivosine, a guanosine derivative, exhibits viral RNA polymerase inhibitory activity and is effective against type A and type B influenza viruses, but its oral effect is not sufficient.
- the present invention provides an antiviral agent that exhibits an effect of preventing infection against various viruses, particularly an influenza virus, and exhibits a therapeutic effect.
- ring A is a substituted or unsubstituted pyrazine, pyrimidine, pyridazine or triazine ring;
- R 1 is ⁇ or OH;
- R 2 is a hydrogen atom, an acyl group or a substituted
- the broken line indicates a single bond or a double bond.
- nitrogen-containing heterocyclic carboxamide derivative represented by the formula (1) or a salt thereof exhibits excellent antiviral activity against various viruses including A, B and C influenza viruses, and has low cytotoxicity. Therefore, it is useful as a highly safe antiviral agent, and is a new substance of the following general formula [la]
- A is a pyrazine ring substituted with a halogen atom, a hydroxyl group or a hydroxy group;
- R 1 is O or OH;
- R 2 is a hydrogen atom, an acryl group or a substituted
- a dashed line indicates a single bond or a double bond.
- the present inventors have found that the nitrogen-containing heterocyclic carboxamide derivative represented by or a salt thereof exerts an excellent antiviral action, thereby completing the present invention.
- a halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom
- an alkyl group means methyl, ethyl, n-propyl Linear or branched C 1 -6 alkyl groups such as benzyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and pentyl; alkenyl groups include vinyl and aryl.
- the consequent opening alkyl group C 3 cyclopropyl, cyclopentyl and cyclo such cyclohexyl - 6 consequent opening alkyl group; a linear or branched C 2 -6 alkenyl group and the alkoxy group, main Linear or branched alkyl-O-groups such as toxic, ethoxy, ⁇ -propoxy, isopropoxy, ⁇ -butoxy, isobutoxy, sec-butoxy, tert-butoxy and benzoyloxy; the Kiruokishi group, Shikuropuro Piruokishi, a C 3-6 consequent opening Alkyl ⁇ Ichiki such cyclopentyloxy Ruo alkoxy and Kishiruokishi cycloheptane; alkylthio groups Main Chiruchio, Echiruchio, n- propylthio, i Sopuropiruchio, n- butylthio, I Sobuchiruchio, sec- butylthi
- cycloalkyl amino group Shikuropuro Piruamino, a C 3 _ 6 consequent opening alkyl one NH- group such Kishiruamino the consequent opening Penchiruami Roh and consequent opening;
- _ 6 alkyl and substituted amino group group halogenoalkyl A group is a triflu A halogen-substituted alkyl group such as methyl, trichloromethyl and chloromethyl; an aryl group includes phenyl and naphthyl groups; an aryloxy group includes an aryl O-group such as phenyloxy and naphthyloxy;
- An arylthio group is an aryl-S- group such as fuerthio and naphthylthio; an arylamino group is an aryl-NH- group such as phenylamino and naphthylamino; an acyl group is a formyl group; , Asechiru, propionyl, Puchir
- oxoxide group means an oxygen atom bonded to a nitrogen atom in the ring; Also, lower means 1 to 6 carbon atoms.
- the carboxyl-protecting group includes all groups that can be used as ordinary carboxyl-protecting groups, such as methyl, ethyl, n-propyl, iso-propyl, 1,1-dimethylpropyl Alkyl groups such as tert-butyl, n-butyl and tert-butyl; aryl groups such as phenyl and naphthyl; benzyl, diphenylmethyl, trityl, p-ditobenzyl, P-methoxybenzyl and bis (p-methyl).
- Aralkyl groups such as toxicphenyl) methyl; acetyl alkyl groups such as acetylmethyl, benzoylmethyl, p-nitrobenzoylmethyl, p-bromobenzoinolemethyl and p-methanesulfonylbenzoinolemethyl; 2-—tetrahydroviranyl and Oxygen-containing heterocyclic groups such as 2-tetrahydrofuranyl; 2,2,2-trichloroethyl and the like Halogenoalkyl group; alkylsilylalkyl group such as 2- (trimethylsilyl) ethyl; alkoxyalkyl group such as acetomethyl, propionyloxymethyl and pivaloyloxymethyl; phthalimidmethyl and succinimidomethyl Nitrogen-containing heterocyclic alkyl groups such as nitrogen; cycloalkyl groups such as hexahexyl; alkoxyalkyl groups such as methoxymethyl, ethoxymethyl and
- Alkenyl groups such as trimethylsilyl, triethylsilinole, triisopropylsilyl, tert-butyl propylsilyl, tert-butyldimethylsilyl, tert-butyldimethylsilyl, tert-butylinolepheninolesilyl, diphenylmethylsilyl and tert-butylmethoxyphenylsilyl. And the like.
- silyls such as trimethylsilyl, triethylsilinole, triisopropylsilyl, tert-butyl propylsilyl, tert-butyldimethylsilyl, tert-butyldimethylsilyl, tert-butylinolepheninolesilyl, diphenylmethylsilyl and tert-butylmethoxyphenylsilyl. And the like.
- the ring A in the general formula [1] represents a pyrazine ring, a pyrimidine ring, a pyridazine ring and a triazine ring, and more specifically, has the following structure.
- * 1 represents a substitution position of R 1
- R 2 is a halogen atom; an alkyl group which may be substituted with a hydroxyl, alkoxy, alkylthio, aryl, amino or alkylamino group; a halogenoalkyl group; an alkenyl group; Alkyl group; hydroxy group; alkoxy group; cycloalkyloxy group; alkoxycarbonyl group; mercapto group; alkylthio group optionally substituted with aryl group; aryl group; aryloxy group; Ruthio group; arylamino group; cyano group; nitro group; amino group which may be substituted with an acyl group; alkylamino group; cycloalkylamino group; acyl group; hydrazino group; Group: carbamoyl group; thiocarbamoyl group; alkyl group may be substituted with one or more substituents selected from rubamoyl group and heterocyclic group.
- Preferred examples of the ring A in the general formula [1] include a pyrazine ring, a pyrimidine ring and a triazine ring. More preferred ring A includes a pyrazine ring.
- substituent of the ring include a halogen atom; an alkyl group which may be substituted by a hydroxyl, alkoxy, alkylthio, aryl, amino or alkylamino group; a halogenoalkyl group; an alkenyl group; Hydroxy group; alkoxy group; cycloalkyl group; alkoxycarbonyl group; mercapto group; alkylthio group optionally substituted with aryl group; aryl group; aryloxy group; arylthio group; arylamino group; An amino group optionally substituted with an acyl group; an alkylamino group; a cycloalkylamino group; an acyl group; a hydra
- Examples of the salt of the compound represented by the general formula [1] include commonly known salts of a basic group such as an amino group or an acidic group such as a hydroxyl group or a carboxyl group.
- Examples of the salt in the basic group include salts with mineral acids such as hydrochloric acid, hydrobromic acid and sulfuric acid; tartaric acid, formic acid, citric acid, trichloroacetic acid and trifluoroacetic acid.
- Salts with organic carboxylic acids and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid, and naphthalenesulfonic acid;
- sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid, and naphthalenesulfonic acid
- alkali metals such as sodium and potassium
- salts with alkaline earth metals such as calcium and magnesium
- ammonium salts and trimethylamine, triethylamine, tributylamine, pyriamine.
- Representative compounds include, for example, the compounds shown in Tables 1 to 4.
- R 2 a -CH (C00H) CH 2 C00H
- R 2 b -CH (CH 3 ) CONHCH (CH 3 ) C00H
- the nitrogen-containing heterocyclic carboxamide derivative represented by the general formula [1] of the present invention or a salt thereof can be obtained by purchasing a commercial product, or a known method or a method similar thereto. It can be produced by methods and by combining them. References describing the production method include, for example, J. Am. Chem. Soc., 71, 78 (1949), J. Am. Chem. Soc., 78, 242-244 (1956). ), J. Heterocycl. Chem., 15 (4), 665-670 (1978), J. Chem. Soc., 1379 (1955), U.S. Pat. No. 5,597,823, and the like.
- the nitrogen-containing heterocyclic carboxamide derivative represented by the general formula [1] of the present invention or a salt thereof can be specifically produced, for example, by the following production methods 1 to 3. Manufacturing method 1
- the compound of the general formula [1] can be obtained by reacting the compound of the general formula [2] with the compound of the general formula [4].
- the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction.
- the solvent include alcohols such as methanol, ethanol and isopropyl alcohol; dichloromethane, and chloroform.
- Halogenated hydrocarbons such as form and dichloroethane; aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as dioxane, tetrahydrofuran, anisole, diethylene glycol getyl ether and dimethylacetosolve; Nitriles such as tritolyl; amides such as ⁇ , ⁇ -dimethylformamide and ⁇ , ⁇ -dimethylacetamide; and sulfoxides such as dimethylsulfoxide. May be used as a mixture.
- the compound of the general formula [4] is used in an amount of at least equimolar to the compound of the general formula [2]. Preferably, it may be used in a 1.0- to 5.0-fold molar amount.
- This reaction is carried out usually at 0 to 100 ° C, preferably at 20 to 80 ° C, for 5 to 24 hours, preferably for 30 minutes to 10 hours.
- the compound of the general formula [1] can be obtained by subjecting the compound of the general formula [3] and the compound of the general formula [4] to a dehydration condensation reaction.
- the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, and examples thereof include dioxane, tetrahydrofuran, anisol, diethylene glycol dimethyl ether and dimethyl cellulose.
- Ethers such as mouth solvents; halogenated hydrocarbons such as dichloromethane, chloroform and ethane; amides such as N, N-dimethylformamide and N, N-dimethylacetamide; These solvents may be used as a mixture.
- the compound of the general formula [4] may be used in an amount of at least an equimolar amount, preferably 1.0 to 2.0 times, the molar amount of the compound of the general formula [3].
- Examples of the dehydrating condensing agent used in this reaction include 1,3-dicyclohexylcarbodiimide, ⁇ , ⁇ '-carbonyldiimidazole and 1-ethyl-3- (3'-dimethylaminopropyl). ) Carbodimid and the like.
- the amount of the dehydrating condensing agent to be used is at least equimolar to the compound of the general formula [3], preferably 1.0 to 2.0 times.
- This reaction is carried out usually at 0 to 100 ° C, preferably at 20 to 60 ° C, for 5 minutes to 24 hours, preferably for 30 minutes to 10 hours.
- the compound of the general formula [1] is obtained by subjecting the compound of the general formula [5] to an alkyl ether cleavage reaction. Can be obtained.
- R 4 is a methyl group
- the method described in PROTECTIVE GROUPS IN ORGANIC SYNTHESIS Second edition JOHN WILEY & SONS ppl 45-149 (1991) or a method similar thereto may be used.
- R 1 , ring A and a dashed line have the same meaning as described above, and R 2a represents an acyl group.
- the compound of the general formula [1c] can be obtained by subjecting the compound of the general formula [lb] to an acylation reaction in the presence of a deoxidizing agent.
- the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction.
- the solvent include dioxane, tetrahydrofuran, anisol, diethylene glycol dimethyl ether, and dimethyl cellulose.
- Ethers such as sorbents in mouth; aromatic hydrocarbons such as benzene, toluene and xylene; halogenated hydrocarbons such as dichloromethane, chloroform and dichloroethane; N, N-dimethylformamide and ⁇ , ⁇ -dimethyla
- amides such as cetamide and water, and these solvents may be used as a mixture.
- the amount of the acylating agent to be used is 1 mole or more, preferably 1.0 to 2.0 moles, per mole of the compound of the general formula [lb].
- Examples of the deoxidizing agent used in this reaction include pyridine, triethylamine, and sodium hydrogencarbonate.
- the amount of the deoxidizing agent to be used is at least equimolar to the compound of the general formula [1b], preferably 1.0 to 2.0 times.
- This reaction is carried out usually at 0 to 100 ° C, preferably at 20 to 60 ° C, for 5 minutes to 24 hours, preferably for 30 minutes to 10 hours.
- the compounds of the general formulas [2], [3], [4], [5] and [1b] can be used in the form of salts thereof. The same salts as described in [1] can be mentioned.
- compounds of the general formulas [2], [3], [4], [5] and [1b] and their salts may be used in various isomers (optically active isomers, positional isomers, etc.) and solvates. If objects exist, any of them can be used.
- the compound of the general formula [1c] to be produced can be a salt, and examples of the salt include the same salts as described in the general formula [1].
- viruses which is a target of the antiviral agent containing the nitrogen-containing heterocyclic carboxamide derivative represented by the general formula [1] of the present invention or a salt thereof include A, B and C type influenza diino.
- Influenza virus is a particularly effective virus.
- the nitrogen-containing heterocyclic carboxamide derivative represented by the general formula [1] of the present invention or a salt thereof can be used as a solution, a suspending agent, a powder, Pharmaceutical preparations such as granules, fine granules, tablets, capsules, syrups, elixirs, alcoholic beverages, lozenges, gargles and aerosols, orally and parenterally (injection, dermal, rectal) In the nasal cavity).
- the administration method, dosage and number of administrations of the antiviral agent of the present invention can be appropriately selected according to the age, weight, and condition of the patient, but usually 1 to 10 mgZKg per day for an adult.
- the administration may be divided into several times to several times.
- a nitrogen-containing heterocyclic carboxamide derivative represented by the general formula [1] or a salt thereof was dissolved in lOmg / mL with dimethyl sulfoxide, and diluted to a predetermined concentration with a culture solution before use.
- MDCK cells canine kidney cells
- Vero cells monkey kidney cells
- MD'-MEM (Nissi) supplemented with 10% fetal calf serum was used for growing MDCK cells and Vero cells, and for performing cytotoxicity tests using Vero cells.
- Test example 1 anti-influenza effect
- Influenza virus A / PR / 8/34 strain was diluted to 200 cells / niL with a serum-free culture medium, and infected and adsorbed at 0.5 mL / well for 1 hour. After completion of infection and adsorption. Add E'-MEM culture solution containing 0.6% agar noble, 1% bovine serum albumin and 3 ⁇ g / mL acetyltrypsin containing the test compound to the specified concentration. After sufficient coagulation. The culture was inverted and cultured for 3 days. After completion of the culture, live cells were stained with 1% neutral red.After fixing the cells with 10% formalin, the agar medium was removed with running water, and the number of plaques was counted. Expressed as a percentage compared to the spiked control.
- Table 5 shows the results.
- the numbers of the test compounds are the same as the numbers of the compounds in Tables 1 to 4.
- Vero cells are prepared at 2 ⁇ 10 4 cells / mL with a culture solution, inoculated at 100 iL / well, and cultured for 4 days at 37 ° (: 5% CO 2.
- XTT The number of viable cells was measured by the method [for example, CANCER RESEARCH, Vol. 48, pp. 4824-2833 (1988)].
- the 50% cytostatic concentration (IC 5Q ) of 3-hydroxy-12-pyrazinecarboxamide (No. 1 compound) was 250 ⁇ g / mL or more.
- All mixing ratios in the eluent are volume ratios.
- silica gel BW-127ZH (manufactured by Fuji Silicon Chemical Co., Ltd.) was used as a carrier in column chromatography;
- LC-SORB SP-B-0DS (manufactured by Chemco) was used as a carrier in reverse phase column chromatography.
- Example 1 0.13 g of 3,5-dihydroxy-16-ethoxycarbonyl-2-pyrazinecarboxamide was suspended in water and OraL and ethanol 1.OmU was suspended at room temperature, and 5 mol / mL sodium hydroxide 0.34 mL was added at room temperature. Stir for an additional 16 hours. Adjust the pH to 2 by adding Imol / mL hydrochloric acid to the reaction mixture. The precipitated crystals are collected by filtration and washed with water to give 0.07 g of 3,5-dihydroxy-6-carboxy1-2-pyrazinecarboxamide.
- An antiviral agent containing the nitrogen-containing heterocyclic carboxamide derivative represented by the general formula [1] or a salt thereof is useful for the prevention and treatment of viral infections, particularly influenza virus infection.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002339272A CA2339272C (en) | 1998-08-20 | 1999-08-18 | Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same |
JP2000565890A JP3453362B2 (ja) | 1998-08-20 | 1999-08-18 | 含窒素複素環カルボキサミド誘導体またはその塩並びにそれらを含有する抗ウイルス剤 |
EP99938504A EP1112743B1 (en) | 1998-08-20 | 1999-08-18 | Nitrogenous heterocyclic carboxamide derivatives or salt thereof as antiviral agents |
DE69937405T DE69937405T2 (de) | 1998-08-20 | 1999-08-18 | Stickstoffheterocyclische Carboxamidverbindungen oder deren Salze als antivirale Mittel |
MXPA01001843A MXPA01001843A (es) | 1998-08-20 | 1999-08-18 | Derivados de carboxamida heterociclica con nitrogeno o sales derivados de los mismos y agentes antivirales que comprenden los mismos. |
HU0103453A HU227475B1 (en) | 1998-08-20 | 1999-08-18 | Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing them |
AU53004/99A AU756635B2 (en) | 1998-08-20 | 1999-08-18 | Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both |
IL14115099A IL141150A (en) | 1998-08-20 | 1999-08-18 | Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing them |
NZ509748A NZ509748A (en) | 1998-08-20 | 1999-08-18 | Nitrogenous heterocyclic carboxamide derivatives or salts useful as antiviral agents |
BRPI9913097A BRPI9913097B8 (pt) | 1998-08-20 | 1999-08-18 | derivado heterocíclico de carboxamida contendo nitrogênio ou um sal do mesmo |
DK99938504T DK1112743T3 (da) | 1998-08-20 | 1999-08-18 | Nitrogenholdige heterocykliske carboxamidderivater eller salte deraf som antivirale midler |
NO20010836A NO321026B1 (no) | 1998-08-20 | 2001-02-19 | Nitrogen-inneholdende heterosykliske karboksamidderivater eller salter derav |
US09/788,992 US6787544B2 (en) | 1998-08-20 | 2001-02-20 | Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same |
US12/869,074 USRE43748E1 (en) | 1998-08-20 | 2010-08-26 | Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/250441 | 1998-08-20 | ||
JP25044198 | 1998-08-20 | ||
JP11/145922 | 1999-05-26 | ||
JP14592299 | 1999-05-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/788,992 Continuation-In-Part US6787544B2 (en) | 1998-08-20 | 2001-02-20 | Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000010569A1 true WO2000010569A1 (fr) | 2000-03-02 |
Family
ID=26476908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/004429 WO2000010569A1 (fr) | 1998-08-20 | 1999-08-18 | Derives heterocycliques azotes de carboxamide ou certains de leurs sels et antiviraux les contenant les deux |
Country Status (25)
Country | Link |
---|---|
US (2) | US6787544B2 (ja) |
EP (1) | EP1112743B1 (ja) |
JP (1) | JP3453362B2 (ja) |
KR (1) | KR100585240B1 (ja) |
CN (2) | CN1154493C (ja) |
AT (1) | ATE376418T1 (ja) |
AU (1) | AU756635B2 (ja) |
BR (1) | BRPI9913097B8 (ja) |
CA (1) | CA2339272C (ja) |
CY (1) | CY1107001T1 (ja) |
CZ (1) | CZ301763B6 (ja) |
DE (1) | DE69937405T2 (ja) |
DK (1) | DK1112743T3 (ja) |
ES (1) | ES2296399T3 (ja) |
HU (1) | HU227475B1 (ja) |
ID (1) | ID28806A (ja) |
IL (1) | IL141150A (ja) |
MX (1) | MXPA01001843A (ja) |
NO (1) | NO321026B1 (ja) |
NZ (1) | NZ509748A (ja) |
PL (1) | PL200955B1 (ja) |
PT (1) | PT1112743E (ja) |
RU (1) | RU2224520C2 (ja) |
TR (1) | TR200100574T2 (ja) |
WO (1) | WO2000010569A1 (ja) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1256588A1 (en) * | 2000-02-16 | 2002-11-13 | Toyama Chemical Co., Ltd. | Novel pyrazine derivatives or salts thereof, pharmaceutical compositions containing the derivatives or the salts and intermediates for the preparation of both |
WO2006137706A1 (en) * | 2005-06-24 | 2006-12-28 | B & C Biopharm. Co., Ltd. | 6-(4-substituted-anilino)pyrimidine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same |
US7169780B2 (en) | 2001-10-26 | 2007-01-30 | Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
JP2007525529A (ja) * | 2004-03-12 | 2007-09-06 | 沈陽薬科大学 | 5−ヒドロキシインドール−3−カルボン酸エステル類誘導体およびその用途 |
WO2007139081A1 (ja) | 2006-05-31 | 2007-12-06 | Toyama Chemical Co., Ltd. | イノシシ科動物またはヒツジ用抗***ウイルス剤およびイノシシ科動物またはヒツジの***の予防または治療方法 |
WO2008099874A1 (ja) * | 2007-02-16 | 2008-08-21 | Toyama Chemical Co., Ltd. | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 |
WO2010104170A1 (ja) | 2009-03-13 | 2010-09-16 | 富山化学工業株式会社 | 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミド含有錠剤および造粒末 |
JP2010241806A (ja) * | 2009-03-18 | 2010-10-28 | Toyama Chem Co Ltd | 3−ヒドロキシ−2−ピラジンカルボキサミドの製造法 |
WO2012043700A1 (ja) | 2010-09-30 | 2012-04-05 | 富山化学工業株式会社 | 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのナトリウム塩 |
WO2012043696A1 (ja) | 2010-09-30 | 2012-04-05 | 富山化学工業株式会社 | 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのメグルミン塩 |
JP2012180336A (ja) * | 2010-11-12 | 2012-09-20 | Fujifilm Corp | ピラジノ〔2,3−d〕イソオキサゾール誘導体 |
WO2013161933A1 (ja) * | 2012-04-26 | 2013-10-31 | 富山化学工業株式会社 | 重水素化含窒素複素環カルボキサミド誘導体 |
WO2013180149A1 (ja) * | 2012-05-30 | 2013-12-05 | 富山化学工業株式会社 | 重水素化含窒素複素環カルボキサミド誘導体またはその塩 |
WO2019131223A1 (ja) | 2017-12-28 | 2019-07-04 | 富士フイルム富山化学株式会社 | 凍結乾燥製剤の製造方法 |
WO2020138067A1 (ja) | 2018-12-25 | 2020-07-02 | 富士フイルム富山化学株式会社 | ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるrnaウイルス感染症治療剤 |
WO2021200651A1 (ja) | 2020-03-30 | 2021-10-07 | 富士フイルム富山化学株式会社 | コロナウイルス感染症治療剤 |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
WO2021221043A1 (ja) | 2020-04-30 | 2021-11-04 | 富士フイルム富山化学株式会社 | ピラジン誘導体と他のコロナウイルス感染症治療薬とを組み合わせてなるコロナウイルス感染症治療剤 |
WO2021241613A1 (ja) | 2020-05-27 | 2021-12-02 | 富士フイルム富山化学株式会社 | ピラジン誘導体とチオプリン誘導体を組み合わせてなるrnaウイルス感染症治療剤 |
WO2022131117A1 (ja) | 2020-12-18 | 2022-06-23 | 富士フイルム富山化学株式会社 | 医薬組成物 |
WO2022131112A1 (ja) | 2020-12-18 | 2022-06-23 | 富士フイルム富山化学株式会社 | 医薬組成物 |
WO2022215616A1 (ja) | 2021-04-08 | 2022-10-13 | 富士フイルム富山化学株式会社 | コロナウイルス感染症治療剤 |
WO2022239823A1 (ja) | 2021-05-14 | 2022-11-17 | 富士フイルム富山化学株式会社 | 新型コロナウイルスの変異ウイルスに対する感染症治療剤 |
WO2023008530A1 (ja) | 2021-07-30 | 2023-02-02 | 富士フイルム富山化学株式会社 | 新型コロナウイルス感染症治療剤 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2456292A1 (en) * | 2001-08-14 | 2003-02-27 | Toyama Chemical Co., Ltd. | Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog |
JP4351053B2 (ja) | 2001-10-26 | 2009-10-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ジヒドロキシピリミジンカルボキサミド系hivインテグラーゼ阻害薬 |
JP4200758B2 (ja) * | 2002-12-26 | 2008-12-24 | 株式会社日立ハイテクノロジーズ | パネルの樹脂塗布方法、ディスプレイ用パネルの製造方法及び樹脂塗布装置 |
US20050119704A1 (en) * | 2003-11-13 | 2005-06-02 | Peters Nicholas S. | Control of cardiac arrhythmias by modification of neuronal conduction within fat pads of the heart |
TWI355894B (en) * | 2003-12-19 | 2012-01-11 | Du Pont | Herbicidal pyrimidines |
CN101289455B (zh) * | 2007-04-17 | 2010-11-10 | 靳广毅 | 一种抗流感病毒前体药及其应用 |
CN102846617B (zh) * | 2011-07-01 | 2016-01-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 3-(丁基氧基)-2-吡嗪甲酰氨的制备方法和用途 |
WO2013004141A1 (zh) * | 2011-07-01 | 2013-01-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 3-烷氧基取代-2-吡嗪甲酰氨类化合物及其用途 |
CN102617491B (zh) * | 2011-07-01 | 2015-05-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 3-氧代-3,4-二氢-2-吡嗪甲酰氨类衍生物、其药物组合物、其制备方法及用途 |
WO2013004092A1 (zh) * | 2011-07-01 | 2013-01-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 3-氧代-3,4-二氢-2-吡嗪甲酰氨类衍生物、其药物组合物、其制备方法及用途 |
CN102603658B (zh) * | 2011-10-18 | 2014-04-30 | 山东齐都药业有限公司 | 6-氟-3-羟基-2-吡嗪酰胺的制备方法 |
CN102603657B (zh) * | 2011-10-18 | 2015-02-04 | 山东齐都药业有限公司 | 6-溴-3-羟基-2-吡嗪酰胺的制备方法 |
FR3000490B1 (fr) * | 2012-12-27 | 2015-03-13 | Anaconda Pharma | Procede de synthese d'une hydrazine utile dans le traitement du virus du papillome |
WO2016120301A1 (en) | 2015-01-28 | 2016-08-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of ebola virus disease |
CN106588786B (zh) * | 2015-10-14 | 2019-03-08 | 山东省药学科学院 | 一种高纯度法匹拉韦杂质的制备方法 |
CN105687152B (zh) * | 2016-03-22 | 2020-04-07 | 山东齐都药业有限公司 | 一种法匹拉韦快速释放药物制剂及制备方法 |
CN106083745B (zh) * | 2016-08-15 | 2018-08-21 | 山东百诺医药股份有限公司 | 6-氟-3-羟基-2-吡嗪酰胺的合成方法 |
CN107226794A (zh) * | 2017-07-17 | 2017-10-03 | 郑州大学 | 一种法匹拉韦的合成方法 |
CN112300083B (zh) * | 2020-04-20 | 2021-08-03 | 常州制药厂有限公司 | 一种法匹拉韦的制备方法 |
CN113563273B (zh) * | 2020-04-28 | 2023-12-26 | 中国人民解放军军事科学院军事医学研究院 | 一种抗病毒的吡嗪酰胺衍生物及其制备方法 |
RU2744429C1 (ru) * | 2020-05-02 | 2021-03-09 | Андрей Александрович Иващенко | Противо-РНК вирусное, в том числе противокоронавирусное средство - замещенный хиноксалин, фармацевтическая композиция и применения |
RU2731932C1 (ru) | 2020-05-07 | 2020-09-09 | Общество с ограниченной ответственностью "Кромис" (ООО "Кромис") | Противо-COVID-19 (SARS-CoV-2) вирусная фармацевтическая композиция |
CN111704582B (zh) * | 2020-06-23 | 2021-06-11 | 杭州煌森生物科技有限公司 | 一种法匹拉韦及其衍生物的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1198688A (en) * | 1966-11-17 | 1970-07-15 | Merck & Co Inc | Pyrazinoylguanidines |
JPS5620576A (en) * | 1979-07-27 | 1981-02-26 | Nippon Soda Co Ltd | Pyrimidine derivative and selective herbicide |
US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3631036A (en) * | 1969-11-04 | 1971-12-28 | American Home Prod | 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds |
US3745161A (en) * | 1970-04-20 | 1973-07-10 | Merck & Co Inc | Phenyl-hydroxy-pyrazine carboxylic acids and derivatives |
US4661145A (en) * | 1977-03-10 | 1987-04-28 | Rohm And Haas Company | Plant growth regulating 1-aryl-1,4-dihydro-4-oxo(thio)-pyridazines |
CA1138872A (en) * | 1979-07-30 | 1983-01-04 | Rohm And Haas Company | Process for the preparation of 1-aryl-1,4- dihydro-4-oxopyridazine-3-carboxamides |
US4545810A (en) * | 1980-08-07 | 1985-10-08 | Sds Biotech Corporation | Herbicidal and plant growth regulant diphenylpyridazinones |
US4404203A (en) * | 1981-05-14 | 1983-09-13 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
US4565814A (en) * | 1983-01-28 | 1986-01-21 | Sanofi | Pyridazine derivatives having a psychotropic action and compositions |
CA2067663A1 (en) * | 1991-05-01 | 1992-11-02 | Hitoshi Tone | Pyrazine derivatives |
FR2705344B1 (fr) | 1993-05-17 | 1995-06-30 | Synthelabo | Dérivés de 2-aminopyrazine-5-carboxamide, leur préparation et leur application en thérapeutique. |
JPH09216883A (ja) * | 1996-02-09 | 1997-08-19 | Fujisawa Pharmaceut Co Ltd | ピラゾロピリジン化合物および該化合物を含有する医薬 |
ATE213495T1 (de) * | 1996-09-16 | 2002-03-15 | Du Pont Pharm Co | Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper |
-
1999
- 1999-08-18 MX MXPA01001843A patent/MXPA01001843A/es active IP Right Grant
- 1999-08-18 RU RU2001104536/15A patent/RU2224520C2/ru active
- 1999-08-18 KR KR1020017001690A patent/KR100585240B1/ko not_active IP Right Cessation
- 1999-08-18 WO PCT/JP1999/004429 patent/WO2000010569A1/ja active IP Right Grant
- 1999-08-18 CZ CZ20010617A patent/CZ301763B6/cs not_active IP Right Cessation
- 1999-08-18 CN CNB998098973A patent/CN1154493C/zh not_active Expired - Lifetime
- 1999-08-18 CA CA002339272A patent/CA2339272C/en not_active Expired - Lifetime
- 1999-08-18 TR TR2001/00574T patent/TR200100574T2/xx unknown
- 1999-08-18 AU AU53004/99A patent/AU756635B2/en not_active Expired
- 1999-08-18 CN CNB2004100325508A patent/CN1275947C/zh not_active Expired - Lifetime
- 1999-08-18 ID IDW20010396A patent/ID28806A/id unknown
- 1999-08-18 JP JP2000565890A patent/JP3453362B2/ja not_active Expired - Lifetime
- 1999-08-18 PL PL346172A patent/PL200955B1/pl unknown
- 1999-08-18 NZ NZ509748A patent/NZ509748A/xx not_active IP Right Cessation
- 1999-08-18 ES ES99938504T patent/ES2296399T3/es not_active Expired - Lifetime
- 1999-08-18 DE DE69937405T patent/DE69937405T2/de not_active Expired - Lifetime
- 1999-08-18 DK DK99938504T patent/DK1112743T3/da active
- 1999-08-18 PT PT99938504T patent/PT1112743E/pt unknown
- 1999-08-18 AT AT99938504T patent/ATE376418T1/de active
- 1999-08-18 EP EP99938504A patent/EP1112743B1/en not_active Expired - Lifetime
- 1999-08-18 BR BRPI9913097A patent/BRPI9913097B8/pt not_active IP Right Cessation
- 1999-08-18 IL IL14115099A patent/IL141150A/xx not_active IP Right Cessation
- 1999-08-18 HU HU0103453A patent/HU227475B1/hu unknown
-
2001
- 2001-02-19 NO NO20010836A patent/NO321026B1/no not_active IP Right Cessation
- 2001-02-20 US US09/788,992 patent/US6787544B2/en not_active Ceased
-
2007
- 2007-11-12 CY CY20071101459T patent/CY1107001T1/el unknown
-
2010
- 2010-08-26 US US12/869,074 patent/USRE43748E1/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1198688A (en) * | 1966-11-17 | 1970-07-15 | Merck & Co Inc | Pyrazinoylguanidines |
JPS5620576A (en) * | 1979-07-27 | 1981-02-26 | Nippon Soda Co Ltd | Pyrimidine derivative and selective herbicide |
US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
Non-Patent Citations (2)
Title |
---|
J. DAUNIS ET. M. FOLLET: "Etude en serie as-triazine", BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, 1975, pages 864 - 870 (3-4, PT. 2), XP002925547 * |
M. KRYSTAL ET AL: "Identification of N-Hydroxamic acid and N-hydroxyimide compounds that inhibit the influenza virus polymerase", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 7, no. 6, 1996, pages 353 - 360, XP002925548 * |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1295890A1 (en) * | 2000-02-16 | 2003-03-26 | Toyama Chemical Co., Ltd. | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof |
EP1256588A4 (en) * | 2000-02-16 | 2003-03-26 | Toyama Chemical Co Ltd | NEW PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THEIR SALTS AND INTERMEDIATES FOR BOTH PRODUCTION |
US6800629B2 (en) | 2000-02-16 | 2004-10-05 | Toyama Chemical Co., Ltd. | Pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof |
EP1256588A1 (en) * | 2000-02-16 | 2002-11-13 | Toyama Chemical Co., Ltd. | Novel pyrazine derivatives or salts thereof, pharmaceutical compositions containing the derivatives or the salts and intermediates for the preparation of both |
US7435734B2 (en) | 2001-10-26 | 2008-10-14 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
US7169780B2 (en) | 2001-10-26 | 2007-01-30 | Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
US7217713B2 (en) | 2001-10-26 | 2007-05-15 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
JP2007525529A (ja) * | 2004-03-12 | 2007-09-06 | 沈陽薬科大学 | 5−ヒドロキシインドール−3−カルボン酸エステル類誘導体およびその用途 |
JP4792025B2 (ja) * | 2004-03-12 | 2011-10-12 | 沈陽薬科大学 | 5−ヒドロキシインドール−3−カルボン酸エステル類誘導体およびその用途 |
WO2006137706A1 (en) * | 2005-06-24 | 2006-12-28 | B & C Biopharm. Co., Ltd. | 6-(4-substituted-anilino)pyrimidine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same |
WO2007139081A1 (ja) | 2006-05-31 | 2007-12-06 | Toyama Chemical Co., Ltd. | イノシシ科動物またはヒツジ用抗***ウイルス剤およびイノシシ科動物またはヒツジの***の予防または治療方法 |
US8815842B2 (en) | 2006-05-31 | 2014-08-26 | Toyama Chemical Co., Ltd. | Anti-foot-and-mouth disease virus agent for animal belonging to family Suidae or sheep, and method for prevention or treatment of foot-and-mouth disease in animal belonging to family Suidae or sheep |
JP5161078B2 (ja) * | 2006-05-31 | 2013-03-13 | 富山化学工業株式会社 | イノシシ科動物またはヒツジ用抗***ウイルス剤およびイノシシ科動物またはヒツジの***の予防または治療方法 |
US8759354B2 (en) | 2007-02-16 | 2014-06-24 | Toyama Chemical Co., Ltd. | Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination |
WO2008099874A1 (ja) * | 2007-02-16 | 2008-08-21 | Toyama Chemical Co., Ltd. | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 |
JP5255456B2 (ja) * | 2007-02-16 | 2013-08-07 | 富山化学工業株式会社 | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 |
KR20110126699A (ko) | 2009-03-13 | 2011-11-23 | 토야마 케미칼 컴퍼니 리미티드 | 6-플루오로-3-히드록시-2-피라진카르복사미드 함유 정제 및 조립분말 |
WO2010104170A1 (ja) | 2009-03-13 | 2010-09-16 | 富山化学工業株式会社 | 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミド含有錠剤および造粒末 |
TWI463999B (zh) * | 2009-03-13 | 2014-12-11 | Toyama Chemical Co Ltd | 含有6-氟-3-羥基-2-吡羧醯胺之錠劑及粒狀粉末 |
JP5583659B2 (ja) * | 2009-03-13 | 2014-09-03 | 富山化学工業株式会社 | 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミド含有錠剤および造粒末 |
US8513261B2 (en) | 2009-03-13 | 2013-08-20 | Toyama Chemical Co., Ltd. | Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
AU2010222029B2 (en) * | 2009-03-13 | 2014-03-27 | Toyama Chemical Co., Ltd. | Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
JP2010241806A (ja) * | 2009-03-18 | 2010-10-28 | Toyama Chem Co Ltd | 3−ヒドロキシ−2−ピラジンカルボキサミドの製造法 |
JP5936546B2 (ja) * | 2010-09-30 | 2016-06-22 | 富山化学工業株式会社 | 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミドのメグルミン塩 |
JPWO2012043700A1 (ja) * | 2010-09-30 | 2014-02-24 | 富山化学工業株式会社 | 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミドのナトリウム塩 |
WO2012043700A1 (ja) | 2010-09-30 | 2012-04-05 | 富山化学工業株式会社 | 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのナトリウム塩 |
WO2012043696A1 (ja) | 2010-09-30 | 2012-04-05 | 富山化学工業株式会社 | 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのメグルミン塩 |
US9090571B2 (en) | 2010-09-30 | 2015-07-28 | Toyama Chemical Co., Ltd. | Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
US9096547B2 (en) | 2010-09-30 | 2015-08-04 | Toyama Chemical Co., Ltd. | Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
JP2012180336A (ja) * | 2010-11-12 | 2012-09-20 | Fujifilm Corp | ピラジノ〔2,3−d〕イソオキサゾール誘導体 |
WO2013161933A1 (ja) * | 2012-04-26 | 2013-10-31 | 富山化学工業株式会社 | 重水素化含窒素複素環カルボキサミド誘導体 |
WO2013180149A1 (ja) * | 2012-05-30 | 2013-12-05 | 富山化学工業株式会社 | 重水素化含窒素複素環カルボキサミド誘導体またはその塩 |
WO2019131223A1 (ja) | 2017-12-28 | 2019-07-04 | 富士フイルム富山化学株式会社 | 凍結乾燥製剤の製造方法 |
US11679083B2 (en) | 2017-12-28 | 2023-06-20 | Fujifilm Toyama Chemical Co., Ltd. | Method for producing freeze-dried formulation |
WO2020138067A1 (ja) | 2018-12-25 | 2020-07-02 | 富士フイルム富山化学株式会社 | ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるrnaウイルス感染症治療剤 |
WO2021200651A1 (ja) | 2020-03-30 | 2021-10-07 | 富士フイルム富山化学株式会社 | コロナウイルス感染症治療剤 |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
WO2021221043A1 (ja) | 2020-04-30 | 2021-11-04 | 富士フイルム富山化学株式会社 | ピラジン誘導体と他のコロナウイルス感染症治療薬とを組み合わせてなるコロナウイルス感染症治療剤 |
WO2021241613A1 (ja) | 2020-05-27 | 2021-12-02 | 富士フイルム富山化学株式会社 | ピラジン誘導体とチオプリン誘導体を組み合わせてなるrnaウイルス感染症治療剤 |
WO2022131117A1 (ja) | 2020-12-18 | 2022-06-23 | 富士フイルム富山化学株式会社 | 医薬組成物 |
WO2022131112A1 (ja) | 2020-12-18 | 2022-06-23 | 富士フイルム富山化学株式会社 | 医薬組成物 |
WO2022215616A1 (ja) | 2021-04-08 | 2022-10-13 | 富士フイルム富山化学株式会社 | コロナウイルス感染症治療剤 |
WO2022239823A1 (ja) | 2021-05-14 | 2022-11-17 | 富士フイルム富山化学株式会社 | 新型コロナウイルスの変異ウイルスに対する感染症治療剤 |
WO2023008530A1 (ja) | 2021-07-30 | 2023-02-02 | 富士フイルム富山化学株式会社 | 新型コロナウイルス感染症治療剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000010569A1 (fr) | Derives heterocycliques azotes de carboxamide ou certains de leurs sels et antiviraux les contenant les deux | |
KR101891933B1 (ko) | B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 피리다존 및 트라이아진온 | |
WO2007028789A1 (en) | Quinazoline derivatives as antiviral agents | |
CA2077732A1 (en) | Heterocyclic derivatives | |
HRP20040098A2 (en) | 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY | |
EP0150507A2 (en) | Cephalosporin derivatives, processes for producing the same and compositions containing them | |
US20060217411A1 (en) | Immunomodulatory compounds | |
EP2268621A1 (en) | Regioselective preparation of substituted pyrimidines | |
EP0123254B1 (en) | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | |
CA2912338A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
EP0341948B1 (en) | Cephalosporins, process for their preparation and pharmaceutical compositions | |
Al‐Omran et al. | New routes to 1‐functionally substituted arylbenzotriazoles: 3‐Benzotriazol‐1‐yl‐pyridazine‐4‐ones, 5‐benzotriazol‐1‐yl‐pyridazine‐6‐ones and 5‐benzotriazol‐1‐yl‐pyridazine‐6‐imines | |
HU201948B (en) | Process for producing cefemcarboxylic acid derivatives and pharmaceutical compositions comprising same | |
SU795467A3 (ru) | Способ получени производныхуРАцилА | |
JP2014503510A (ja) | その構造内にグルタミン酸部分を有する葉酸拮抗薬の新規な製造方法 | |
ZA200101101B (en) | Nitrogenous heterocyclic carboxamide derivatives of salts thereof and antiviral agents containing both. | |
JPH08151368A (ja) | 新規なナフチリドンまたはキノロン化合物もしくはそれらの塩、それらからなる抗ウイルス剤 | |
WO1996009296A1 (fr) | Derive d'arylthiadiazole et agent antiviral le contenant | |
PT576211E (pt) | Processo para sintese de intermediarios de 4-hidroxi-5-helopirrolo-2,3-d-pirimidina | |
JPH0222284A (ja) | セフアロスポリン化合物、その製法及び中間体並びに該化合物を含有する抗菌性医薬組成物 | |
JPH05271204A (ja) | 新規なトリアジン誘導体 | |
Kotb et al. | Efficient synthesis and molecular modeling of new N-/S-nucleosides and schiff, s bases of tetrahydropyrimidine scaffold as potential H5N1 avian influenza a virus inhibitors | |
El-Hashash et al. | Pyran and pyridine as building blocks in heterocyclic synthesis | |
JPS60166689A (ja) | セフアロスポリン誘導体およびその製造法 | |
IL141442A (en) | Guanidine derivatives of cephalosporins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99809897.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 141150 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 53004/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2339272 Country of ref document: CA Ref document number: 2339272 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 509748 Country of ref document: NZ Ref document number: IN/PCT/2001/144/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/01101 Country of ref document: ZA Ref document number: 1020017001690 Country of ref document: KR Ref document number: 200101101 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999938504 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-617 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/001843 Country of ref document: MX Ref document number: 09788992 Country of ref document: US Ref document number: 2001/00574 Country of ref document: TR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999938504 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017001690 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-617 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 53004/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017001690 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999938504 Country of ref document: EP |